For example, approximately only 1% of all tumour mutations generate a neoantigen with sufficient affinity for MHC to prime T cell responses; therefore, determining how to define a high-quality neoantigen which can trigger robust immune responses still presents a significant challenge. Here, HLA-C is linked to neoplasm.